ClinicalTrials.gg
Not yet recruitingNCT07059910Updated Jul 17, 2025

Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment

An observational study in Immune Thrombocytopenic Purpura and Thyroid Disorders, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment

Read the detailed description

We investigate patients with ITP for screening of thyroid disorders and how to deal with it and effect of this on the ttt

02

Conditions studied

  • Immune Thrombocytopenic Purpura
  • Thyroid Disorders
03

In context

Purpura, Thrombocytopenic, Idiopathic

503 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 158 are open to participants now.

This study's planned enrollment of 100 is below the median of 122 across 99 observational studies indexed under Purpura, Thrombocytopenic, Idiopathic.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

prospective cross sectional study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ITP patients will be classified as newly diagnosed, persistent and chronic based on duration less than 3 months, 3-12 months, and more than 12 months respectively.

    • ITP patients.

Exclusion criteria

Exclusion Criteria:

  • patients with history of thyroidectomy

    • patients with history of drug induced ITP
    • patients with history of , and infection.
    • Patients who refuse to contribute in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients known ITP

    Patients known ITP either newly diagnosed, chronic, refractory Age 18 yrs and above Patients with thyrodiectomy will not be in our study

    Diagnostic Test: Search for thyroid disorders · Diagnostic Test: Laboratory test · Drug: Steroid and eltrombopage

Interventions

  • Diagnostic testSearch for thyroid disorders

    TSH , FT3 , FT4

    Also known as: Laboratory test

  • Diagnostic testLaboratory test

    Search for anti thyroid antibodies

  • DrugSteroid and eltrombopage

    See when we treat thyroid disorders, will patient respond to steroid or eltrombopage?

    Also known as: Drugs used in ITP

06

What researchers measure

Primary outcomes

  1. Assess the frequency of thyroid disorders in patients with IT

    Screening of thyroid disorders in patients with ITP

    Time frame: Assess the frequency of thyroid disorders in patients with IT

  2. Evaluate the treatment of thyroid disorders in improvement in platelets count.

    Evaluate if patients have managed according to thyroid disorders, will this affect in their response to ITP management

    Time frame: Evaluate the treatment of thyroid disorders in improvement in platelets count.

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07059910
Lead sponsor
Assiut University
Responsible party
Ayah Ibrahim Nemr (Assiut, Assiut University) — Principal investigator
First posted
Jul 11, 2025
Start date
Jul 2025 (estimated)
Primary completion
May 31, 2026 (estimated)
Completion
Aug 15, 2026 (estimated)
Last update
Jul 17, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion